Apollo Endosurgery, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apollo Endosurgery, Inc.
Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.
Boston Scientific is greatly increasing its GI endosurgery capabilities with the acquisition of Apollo Endosurgery, a manufacturer of various device for weight loss-related surgeries.
In Scrip’s new column tracking clinical trial developments, NewAmsterdam, CatalYm, Verve, Bellerophon and Almirall announced new trials or changes to existing ones, while CROs Parexel and PPD announced new programs and CTI appointed a new exec.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Lpath Inc.
- Lpath Therapeutics Inc.
- Neighborhood Connections, Inc.